Effect of rosuvastatin on outcomes in chronic haemodialysis patients - Design and rationale of the AURORA study

Current Controlled Trials in Cardiovascular Medicine

Volumn 6, Issue , 2005, Pages

  Fellström, Bengt ^a   Zannad, Faiez ^b   Schmieder, Roland ^c   Holdaas, Hallvard ^d   Jardine, Alan ^e   Rose, Helen ^f   Wilpshaar, Wim ^f   Bannister, K ^g   Beutler, J ^g   Chae, D ^g   Cobbe, S M ^g   Vazquez, B Espinoza ^g   Gronhagen Riska, C ^g   Lima, J ^g   Lins, R ^g   McMahon, A ^g   Mayer, G ^g   Parving, H ^g   Remuzzi, G ^g   Samuelsson, O ^g   Sonkodi, S ^g   Suleymanlar, G ^g   Tesar, V ^g   Tsakiris, D ^g   Todorov, V ^g   Wiecek, A ^g   Wuthrich R ^g   Dargie, H ^g   Ritz, E ^g   Wedel, H ^g   Zwinderman, A H ^g   Brady, A ^g   Deighan, C ^g   Gaw, A ^g   Macfarlane, P ^g   Stott, D ^g   more..

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Ctr Hospitalier Univ de Nancy   (France)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e WESTERN INFIRMARY   (United Kingdom)

^f ASTRAZENECA   (United Kingdom)

^g NONE

Author keywords

Atherosclerosis; Cardiovascular disease; End stage renal disease; Haemodialysis; Lipids; Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEART DEATH; HEART INFARCTION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STROKE; SURVIVAL; TREATMENT OUTCOME;

EID: 27544489356     PISSN: 14686694     EISSN: 14686694     Source Type: Journal    
DOI: 10.1186/1468-6708-6-9     Document Type: Article

References (53)

1. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP: Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994, 9:1136-1142.
2. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32:S112-S119.
3. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr: Controlling the epidemic of cardiovascular disease in chronic renal disease. National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998, 32:853-906.
4. Parfrey PS: Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 2000, 15(Suppl 5):58-68.
5. US Renal Data System: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2000. In Annual Data Report Bethesda, MD; 2000.
6. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Eng J Med 1974, 290:697-701.
7. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
8. Shepherd J, Cobbe SM, Ford I. Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med 1995, 333:1301-1307.
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996, 335:1001-1009.
10. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998, 279:1615-1622.
11. The Long-term intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med 1998, 339:1349-1357.
12. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study or cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
13. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, MacFlarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG: Pravastatin, in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
14. Sever PS, Dahlöf B, Poulter NR, Wedel H., Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, Obrien E, Ötergren J, for the ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcome. Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
15. Laufs U: Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 2003, 58:719-731.
16. Shoji T, Nishizawa Y, Kawagishi T, Tanka M, Kawasaki K, Tabata T, Inoue T, Morii H: Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 1997, 131:229-236.
17. Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii, H: Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998, 9:1277-1284.
18. Baigent C, Landry M: Study of Heart and Renal Protection (SHARP). Kidney Int 2003, 63(Suppl 84):207-210.
19. Baigent C, Buroury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet 2000, 356:147-152.
20. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004, 291:451-459.
21. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients, Kidney Int 2002, 61:297-304.
22. Kidney Disease Outcomes Quality Initiative: Managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003, 41 (Suppl 3):S1-S91.
23. Wanner C, Krane V, Marz W, Olschewski M, Asmus HG, Kramer W, Kuhn KW, Kuteweyer H, Mann JF, Ruf G, Ritz E, Deutsche Diabetes-Dialyse-Studie (4D) Study Group: Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res 2004, 27:259-266.
24. Wanner C: Results of a randomized controlled trial with atorvastatin in dialyzed diabetic patients (4D trial). In Presented at the annual meeting of the American Society of Nephrology St Louis, Missouri, USA. 29 October 2004
25. Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A: Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003, 91:3C-10C.
26. Chapman MJ, Caslake M, Packard C, McTaggart F: New dimension of stacin action on apoB atherogenicity. Clin Cardiol 2003, 26(Suppl 1):17-110.
27. Brewer HB Jr: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003, 92(Suppl 2):23-29.
28. Cox D: Regression models and life tablets (with discussion). J Royal Stat Soc 1972, 74:187-220.
29. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260:1917-1921.
30. Campos H, Genest JJ Jr, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PW, Schaefer EJ: Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992, 12:187-195.
31. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 1997, 95:69-75.
32. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stamfer MJ, Pfeffer MA, Braunwald E: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol Recurrent Events (CARE) trial. Circulation 2000, 102:1886-1892.
33. O'Neal D, Lee P, Murphy B, Best J: Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996, 27:84-91.
34. Königer M, Quaschning T, Wanner C, Schollmeyer P, Krämer-Guth A: Abnormalities in lipoprotein metabolism in hemodialysis patients. Kidney Int 1999, 56(Suppl 71):S248-S250.
35. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ: Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 2000, 35:852-862.
36. Wanner C, Quaschning T: Dyslipidemia and renal disease: pathogenesis and clinical consequences. Curr Opin Nephrol Hypertens 2001, 10:195-201.
37. Fytili CI, Progia EG, Panagoustsos SA, Thodis ED, Passadakis PS, Sombolos KI, Vargemezis VA: Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail 2002, 24:623-630.
38. Wanner C, Horl WH, Luley CH, Wieland H: Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 1991, 39:754-760.
39. Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T, Inoue T, Morii H: Reduction of Intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clin Nephrol 1995, 43:268-277.
40. Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H: Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int 1999, 56(Suppl 71):S134-S136.
41. Nishikawa O, Mune M, Miyano M, Nishide T, Maeda A, Kimura K, Takahashi T, Kishino M, Tone Y, Otani H, Ogawa A, Maeda T, Yukawa S: Effect of simvastatin on the lipid profile of hemodialysis patients. Kidney Int 1999, 56(Suppl 71):S219-S221.
42. Saltissi D, Morgan C, Rogby RJ, Westhuyzen J: Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 2002, 39:283-290.
43. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR, Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024-2031.
44. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW: Comparison of the efficacy and safety of rosuvastatin versus atorvasatatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cordial 2003, 92:152-160.
45. Olsson AG, NcTaggart F, Raza A: Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002, 20:303-328.
46. Locatelli F, Canaud B, Eckardt K-U, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003, 18:1272-1280.
47. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B: Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 2001, 12:2747-2752.
48. Rosenson RS: Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004, 173:1-12.
49. Annuk M, Lind L, Linde T, Fellström B: Impaired endothelium-dependent vasodilation in renal failure in humans. Nephrol Dial Transplant 2001, 16:302-306.
50. Stalker TJ, Lefer AM, Scalia R: A new HMG-Co A reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 2001, 133:406-412.
51. Foley RN: Clinical epidemiology of cardiac disease in dialysis patients: ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial 2003, 16:111-117.
52. Su SF, Hsiao CL, Chu CW, Lee BC, Lee TM: Effects of pravastatin on left ventricular mass in patients with hyperlipidaemia and essential hypertension. Am J Cardiol 2000, 86:514-518.
53. Kjekshus J, Puderson TR, Olsson AG, Faergeman O, Pyörälä L: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997, 3:249-254.